Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) and Kezar Life Sciences (NASDAQ:KZR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.
Risk and Volatility
Tectonic Therapeutic has a beta of 3.27, indicating that its stock price is 227% more volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.
Profitability
This table compares Tectonic Therapeutic and Kezar Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tectonic Therapeutic | N/A | -32.33% | -30.92% |
| Kezar Life Sciences | N/A | -55.42% | -47.87% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tectonic Therapeutic | 1 | 0 | 6 | 1 | 2.88 |
| Kezar Life Sciences | 2 | 4 | 0 | 0 | 1.67 |
Tectonic Therapeutic currently has a consensus price target of $80.57, indicating a potential upside of 188.17%. Kezar Life Sciences has a consensus price target of $6.00, indicating a potential downside of 17.70%. Given Tectonic Therapeutic’s stronger consensus rating and higher probable upside, research analysts clearly believe Tectonic Therapeutic is more favorable than Kezar Life Sciences.
Earnings & Valuation
This table compares Tectonic Therapeutic and Kezar Life Sciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tectonic Therapeutic | N/A | N/A | -$74.15 million | ($4.46) | -6.27 |
| Kezar Life Sciences | $7.00 million | 7.70 | -$56.03 million | ($7.66) | -0.95 |
Kezar Life Sciences has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 9.3% of Kezar Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Tectonic Therapeutic beats Kezar Life Sciences on 9 of the 13 factors compared between the two stocks.
About Tectonic Therapeutic
Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
About Kezar Life Sciences
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.
